Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Prior evidence of a possible link between vitamin D status and hematologic malignancy (HM) in humans comes from observational studies, leaving unresolved the question of whether a true causal relationship exists.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults.

The authors performed a secondary analysis of data from the Women's Health Initiative Calcium/Vitamin D (CaD) trial, a large randomized controlled trial of CaD supplementation compared with placebo in older women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

HMs were classified by cell type (lymphoid, myeloid, or plasma cell) and analyzed as distinct endpoints in secondary analyses.

What Was Measured

The subject headings attached to it are Calcium, Cause of Death, Confidence Intervals, Dietary Supplements, Hematologic Neoplasms, Incidence and Kaplan-Meier Estimate.

The authors tagged it with the keywords epidemiology, lymphoma, risk factors, vitamin D and women.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Cancer), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.